Cargando…
Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)
The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002–2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be ev...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1847333/ https://www.ncbi.nlm.nih.gov/pubmed/17227689 http://dx.doi.org/10.1016/j.vaccine.2006.11.055 |
_version_ | 1782132883162398720 |
---|---|
author | Vogel, Leatrice N. Roberts, Anjeanette Paddock, Christopher D. Genrich, Gillian L. Lamirande, Elaine W. Kapadia, Sagar U. Rose, John K. Zaki, Sherif R. Subbarao, Kanta |
author_facet | Vogel, Leatrice N. Roberts, Anjeanette Paddock, Christopher D. Genrich, Gillian L. Lamirande, Elaine W. Kapadia, Sagar U. Rose, John K. Zaki, Sherif R. Subbarao, Kanta |
author_sort | Vogel, Leatrice N. |
collection | PubMed |
description | The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002–2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be evaluated in animal models. The aged BALB/c mouse model for SARS supports a high level of viral replication in association with clinical illness and disease that mimics SARS in the elderly. We tested two preventive strategies, vaccination and passive transfer of serum antibody, to determine the extent of protection achieved against SARS-CoV challenge in this model. These approaches were able to achieve or induce antibody titers sufficient to reduce viral load, protect from weight loss and reduce or eliminate histopathologic changes in the lungs of aged mice. This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis. |
format | Text |
id | pubmed-1847333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-18473332007-04-02 Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) Vogel, Leatrice N. Roberts, Anjeanette Paddock, Christopher D. Genrich, Gillian L. Lamirande, Elaine W. Kapadia, Sagar U. Rose, John K. Zaki, Sherif R. Subbarao, Kanta Vaccine Short Communication The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002–2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be evaluated in animal models. The aged BALB/c mouse model for SARS supports a high level of viral replication in association with clinical illness and disease that mimics SARS in the elderly. We tested two preventive strategies, vaccination and passive transfer of serum antibody, to determine the extent of protection achieved against SARS-CoV challenge in this model. These approaches were able to achieve or induce antibody titers sufficient to reduce viral load, protect from weight loss and reduce or eliminate histopathologic changes in the lungs of aged mice. This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis. Elsevier Science 2007-03-08 2006-12-11 /pmc/articles/PMC1847333/ /pubmed/17227689 http://dx.doi.org/10.1016/j.vaccine.2006.11.055 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Vogel, Leatrice N. Roberts, Anjeanette Paddock, Christopher D. Genrich, Gillian L. Lamirande, Elaine W. Kapadia, Sagar U. Rose, John K. Zaki, Sherif R. Subbarao, Kanta Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) |
title | Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) |
title_full | Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) |
title_fullStr | Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) |
title_full_unstemmed | Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) |
title_short | Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) |
title_sort | utility of the aged balb/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (sars-cov) |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1847333/ https://www.ncbi.nlm.nih.gov/pubmed/17227689 http://dx.doi.org/10.1016/j.vaccine.2006.11.055 |
work_keys_str_mv | AT vogelleatricen utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT robertsanjeanette utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT paddockchristopherd utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT genrichgillianl utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT lamirandeelainew utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT kapadiasagaru utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT rosejohnk utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT zakisherifr utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov AT subbaraokanta utilityoftheagedbalbcmousemodeltodemonstratepreventionandcontrolstrategiesforsevereacuterespiratorysyndromecoronavirussarscov |